Literature DB >> 14688394

Transplanted bone marrow cells preferentially home to the vessels of in situ generated murine tumors rather than of normal organs.

Anne Dwenger1, Felicia Rosenthal, Márcia Machein, Cornelius Waller, Alexandros Spyridonidis.   

Abstract

Transplanted bone marrow-derived (BM) cells have been shown to home into the tumor vessels of s.c. implanted tumor models and to functionally contribute to tumor neoangiogenesis and tumor growth. However, whether BM cells contribute to the vessels of in situ developing tumors remains unknown. We have taken advantage of the in situ generation of mammary tumors in transgenic mice carrying the polyoma virus middle T oncogene (MMTV-PyVT) to determine whether transplanted BM cells home to and incorporate into the intratumoral vessels. Unfractionated BM from lacZ+ROSA 26 mice was used to rescue irradiated MMTV-PyVT transgenic mice or their wild-type congenics. All transgenic mice were sacrificed when they developed easily palpable mammary tumors. BM cells recruited and incorporated into the vasculature were identified by coexpression of lacZ and CD31, evidence that these cells had a distinctive, elongated appearance and that they lined the vessel structures. We found that BM cells home to and incorporate into 1.3% of the vessels of all in situ generated mammary adenocarcinomas examined (n=8). In contrast, BM cells did not recruit into the vessels of colon or liver of the tumor-bearing mice. Whether these cells contribute to new vessel formation via vasculogenesis or angiogenesis or simply attach to, and integrate into, the growing tips or shafts of pre-existing vessels has to be determined. BM could be used as a vehicle for the specific transport of antiangiogenic signals into the tumor vascular bed.

Entities:  

Mesh:

Year:  2004        PMID: 14688394     DOI: 10.1634/stemcells.22-1-86

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  7 in total

1.  VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature.

Authors:  Krishna Reddy; Ying Cao; Zhichao Zhou; Ling Yu; Shu-Fang Jia; Eugenie S Kleinerman
Journal:  Angiogenesis       Date:  2008-03-16       Impact factor: 9.596

2.  Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor.

Authors:  Krishna Reddy; Zhichao Zhou; Shu-Fang Jia; Tim H Lee; Jaime Morales-Arias; Ying Cao; Eugenie S Kleinerman
Journal:  Int J Cancer       Date:  2008-08-15       Impact factor: 7.396

3.  Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease.

Authors:  Hikaru Sugimoto; Thomas M Mundel; Malin Sund; Liang Xie; Dominic Cosgrove; Raghu Kalluri
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-28       Impact factor: 11.205

4.  Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor.

Authors:  Svetlana Komarova; Justin Roth; Ronald Alvarez; David T Curiel; Larisa Pereboeva
Journal:  J Ovarian Res       Date:  2010-05-25       Impact factor: 4.234

Review 5.  Mesenchymal stem cells as vectors for lung disease.

Authors:  Michael R Loebinger; Elizabeth K Sage; Sam M Janes
Journal:  Proc Am Thorac Soc       Date:  2008-08-15

6.  Stromal-cell-derived Factor 1-α Promotes Tumor Progression in Colorectal Cancer.

Authors:  Se Jun Park; Tae Sung Ahn; Sung Woo Cho; Chang Jin Kim; Dong Jun Jung; Myung Won Son; Sang Ho Bae; Eung Jin Shin; Moon Soo Lee; Chang Ho Kim; Moo Jun Baek
Journal:  J Korean Soc Coloproctol       Date:  2012-02-29

7.  Levels of a subpopulation of platelets, but not circulating endothelial cells, predict early treatment failure in prostate cancer patients after prostatectomy.

Authors:  C K E Wong; B Namdarian; J Chua; X Chin; R Speirs; T Nguyen; M Fankhauser; J Pedersen; A J Costello; N M Corcoran; C M Hovens
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.